Skip NavigationSkip to Content
Return Return to Search Results

Detailed DNA methylation profiles of the E-cadherin promoter in the NCI-60 cancer cells

  1. Author:
    Reinhold, W. C.
    Reimers, M. A.
    Maunakea, A. K.
    Kim, S.
    Lababidi, S.
    Scherf, U.
    Shankavaram, U. T.
    Ziegler, M. S.
    Stewart, C.
    Kouros-Mehr, H.
    Cui, H. M.
    Dolginow, D.
    Scudiero, D. A.
    Pommier, Y. G.
    Munroe, D. J.
    Feinberg, A. P.
    Weinstein, J. N.

  2. Author Address

    NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH,Genom & Bioinformat Grp, Bethesda, MD 20892 USA. Gene Logic, Gaithersburg, MD USA. NCI, Sci Applicat Int Corp, Frederick Inc, Frederick, MD 21701 USA. Johns Hopkins Univ, Sch Med, Dept Med, Epigenet Unit, Baltimore, MD 21205 USA.;Reinhold, WC, NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH,Genom & Bioinformat Grp, Bldg 37,Room 5056, Bethesda, MD 20892 USA.;wcr@mail.nih.gov
    1. Year: 2007
    2. Date: Feb
  2. Journal: Molecular Cancer Therapeutics
    1. 6
    2. 2
    3. Pages: 391-403
  4. Type of Article: Article
  5. ISSN: 1535-7163
  1. Abstract:

    E-cadherin (E-cad) is a transmembrane adhesion glycoprotein, the expression of which is often reduced in invasive or metastatic tumors. To assess E-cad's distribution among different types of cancer cells, we used bisulfite-sequencing for detailed, base-by-base measurement of CpG methylation in E-cad's promoter region in the NCI-60 cell lines. The mean methylation levels of the cell lines were distributed bimodally, with values pushed toward either the high or low end of the methylation scale. The 38 epithelial cell lines showed substantially lower (28%) mean methylation levels compared with the nonepithelial cell lines (58%). The CpG site at -143 with respect to the transcriptional start was commonly methylated at intermediate levels, even in cell lines with low overall DNA methylation. We also profiled the NCI-60 cell lines using Affymetrix U133 microarrays and found E-cad expression to be correlated with E-cad methylation at highly statistically significant levels. Above a threshold of similar to 20% to 30% mean methylation, the expression of E-cad was effectively silenced. Overall, this study provides a type of detailed analysis of methylation that can also be applied to other cancer-related genes. As has been shown in recent years, DNA methylation status can serve as a biomarker for use in choosing therapy.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1158/1535-7163.mct-06-0609
  3. View record in Web of Science®
  4. WOS: 000244262700001

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel